Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.39 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19355051 | 0.83 | — | — | |
| SCHEMBL21360921 | 0.76 | GAA (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22946906 | 0.75 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18531755 | 0.74 | — | — | |
| SCHEMBL19850417 | 0.74 | — | — | |
| SCHEMBL12530342 | 0.74 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22644280 | 0.74 | — | — | |
| SCHEMBL19562987 | 0.74 | — | — | |
| SCHEMBL25720236 | 0.74 | TRPA1 (0.31) | — | |
| SCHEMBL10146184 | 0.73 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065987-A1 | ANTI-CANCER ACTIVITY OF ADAMANTANE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11877506-B2 | Polycyclic aromatic compound | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11859152-B2 | Substrate pattern filling composition and use of the same | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-20230355514-A1 | PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11723589-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230002430-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220402920-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220213415-A1 | SUBSTRATE PATTERN FILLING COMPOSITION AND USE OF THE SAME | MERCK PATENT GMBH (DE) | 2022-07-07 | — | — | US | disclosed |
| US-20220109120-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-04-07 | — | — | US | disclosed |
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2017183734-A1 | PRODRUG OF AMINO ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | WO | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170211023-A1 | SUPRAMOLECULAR CAPSULES | AQDOT LTD (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170028374-A1 | SUPRAMOLECULAR CAPSULES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| EP-2966057-A1 | METHOD FOR ALKYLATION OF AMINES | Takasago International Corporation (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-1999091-B1 | SYNTHESIS OF SUBSTITUTED FLUORENES | TOTAL PETROCHEMICALS RES FELUY (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2007106525-A1 | PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11877506-B2 | Polycyclic aromatic compound | F11, C1R, RNF31 | GRIN2D 2821/4885GRIN3B 3619/4885GRIN1 1601/4885 |
| US-11723589-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | ACHE, ADORA2A, COMT | GRIN2D 213/4885GRIN3B 151/4885GRIN1 302/4885 |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | GRIN2D 3420/4885GRIN3B 2431/4885GRIN1 2447/4885 |
| US-20220109120-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, CHRM1, SOD1 | GRIN2D 193/4885GRIN3B 885/4885GRIN1 972/4885 |
| US-20240065987-A1 | ANTI-CANCER ACTIVITY OF ADAMANTANE DERIVATIVES | TP53, KRAS, MMP9 | GRIN2D 1706/4885GRIN3B 950/4885GRIN1 539/4885 |
| US-20230355514-A1 | PHARMACEUTICAL FORMULATIONS | MC2R, ADCYAP1R1, PCSK9 | GRIN2D 2969/4885GRIN3B 2085/4885GRIN1 2905/4885 |
| US-20230002430-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | CHRM1, L1CAM, SOD1 | GRIN2D 543/4885GRIN3B 1572/4885GRIN1 211/4885 |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | GRIN2D 4216/4885GRIN3B 2263/4885GRIN1 1949/4885 |
| US-20220402920-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | DPYD, PNP, TYMP | GRIN2D 3443/4885GRIN3B 2983/4885GRIN1 3883/4885 |
| US-20170028374-A1 | SUPRAMOLECULAR CAPSULES | TBCB, NOD2, ICOSLG | GRIN2D 1087/4885GRIN3B 1268/4885GRIN1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.